West Pharmaceutical Services (NYSE:WST) is scheduled to announce its earnings results before the market opens on Thursday, October 24th. Analysts expect the company to announce earnings of $0.70 per share for the quarter. West Pharmaceutical Services has set its FY 2019 guidance at $3.00-3.10 EPS and its FY19 guidance at $3.00-3.10 EPS.Investors that are interested in participating in the company’s conference call can do so using this link.
West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.17. The business had revenue of $469.70 million during the quarter, compared to analysts’ expectations of $459.90 million. West Pharmaceutical Services had a net margin of 12.94% and a return on equity of 16.93%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.70 EPS. On average, analysts expect West Pharmaceutical Services to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
WST stock opened at $138.82 on Wednesday. West Pharmaceutical Services has a 1 year low of $91.75 and a 1 year high of $152.10. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.02 and a quick ratio of 2.27. The stock has a market cap of $10.39 billion, a price-to-earnings ratio of 49.40, a P/E/G ratio of 3.29 and a beta of 1.28. The company has a 50 day simple moving average of $142.74 and a 200 day simple moving average of $129.59.
WST has been the topic of a number of research reports. ValuEngine lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Bank of America raised shares of West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a report on Friday, July 26th. Finally, Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $158.00 target price on the stock in a report on Saturday, August 3rd. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $130.72.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Featured Article: Why are percentage gainers important?
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.